US FDA approves Bristol Myers Squibb's cancer drug for Hodgkin's lymphoma

US FDA approves Bristol Myers Squibb's cancer drug for Hodgkin's lymphoma | Reuters March 20 (Reuters) - The U.S. Food and Drug Administration on Friday approved Bristol Myers Squibb's (BMY.N), opens new tabcombination treatment for adults and adolescents aged 12 and older with previously untreated Stage III or IV classical Hodgkin's lymphoma. Sign up here. Reporting by Siddhi Mahatole in Bengaluru; Editing by Shailesh Kuber Our Standards: The Thomson Reuters Trust Principles., opens new tab Purchase Licens ...